Evidence map›Paper›PMID 34049607›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2021

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.

S Oelofse, A Esmail, A H Diacon, F Conradie, O Olayanju, N Ngubane, P Howell, D Everitt, A M Crook, C M Mendel and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
  12. Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
  13. Article
  14. Review
  15. Pretomanid for tuberculosis treatment: an update for clinical purposes.Current research in pharmacology and drug discovery · 2022
    Review
  16. The pipeline of new molecules and regimens against drug-resistant tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

S OelofseCentre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town (UCT), Cape Town, South Africa.
A EsmailCentre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town (UCT), Cape Town, South Africa.
A H DiaconTask Applied Science and Stellenbosch University, Cape Town, South Africa.
F ConradieClinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa, Sizwe Tropical Disease Hospital, Sandringham, South Africa.
O OlayanjuCentre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town (UCT), Cape Town, South Africa.
N NgubaneTask Applied Science and Stellenbosch University, Cape Town, South Africa, King DinuZulu Hospital Complex, Durban, South Africa.
P HowellClinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa, Sizwe Tropical Disease Hospital, Sandringham, South Africa.
D EverittTB Alliance, New York, NY, USA.
A M CrookInstitute of Clinical Trials and Methodology, University College London, London, UK.
C M MendelTB Alliance, New York, NY, USA.
G H WillsInstitute of Clinical Trials and Methodology, University College London, London, UK.
M OlugbosiTB Alliance, Pretoria, South Africa.
A Del ParigiTB Alliance, New York, NY, USA.
E SunTB Alliance, New York, NY, USA.
A CalatroniRho Federal Systems Division, Inc., Durham, NC, USA.
M SpigelmanTB Alliance, New York, NY, USA.
K DhedaCentre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town (UCT), Cape Town, South Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
TB Alliance · USUniversity of Cape Town · ZAMRC Clinical Trials Unit at UCL · GBRho (United States) · USStellenbosch University · ZATask Applied Science · ZAUniversity College London · GB

Funding

Department of HealthMedical Research Council MC_UU_00004/04Medical Research Council MC_UU_12023/27
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Extensively Drug-Resistant TuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsDiarylquinolinesHumansLinezolidNitroimidazolesProspective StudiesAntitubercular AgentsbedaquilineDiarylquinolinesLinezolidNitroimidazolespretomanid

Identifiers

PMID34049607
PMCPMC8171246
OpenAlexW3164976415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.